Mounjaro UK Eligibility Guide (2026):
BMI Rules, Requirements & Exceptions

In the UK, access to Mounjaro (tirzepatide) for weight management is governed by NICE technology appraisal TA1026. While Mounjaro is available as a private prescription, most responsible providers follow these evidence-based clinical guidelines.

If your BMI is between 27 and 29.9, you need at least one weight-related health condition to qualify. The following are commonly accepted:

Commonly accepted conditions

• Type 2 diabetes or prediabetes
• High blood pressure (hypertension)
• High cholesterol (dyslipidaemia)
• Obstructive sleep apnoea
• Cardiovascular disease (existing or high risk)
• Non-alcoholic fatty liver disease (NAFLD / MASLD)

Conditions accepted by some providers

• Polycystic ovary syndrome (PCOS) — with associated weight and metabolic challenges
• Weight-related joint pain (osteoarthritis)
• Weight-related mental health conditions — depression or anxiety significantly worsened by weight

Eligibility policies vary between providers. Always confirm the specific criteria with your chosen pharmacy or clinic before booking a consultation.

Standard BMI thresholds were originally derived from studies in predominantly white European populations. Research consistently shows that people from certain ethnic backgrounds face higher metabolic risk at lower BMI levels—meaning the standard thresholds underestimate health risk for these groups.

The NHS BMI calculator and NICE guidance both recognise lower BMI thresholds for the following groups:

• South Asian backgrounds (Indian, Pakistani, Bangladeshi, Sri Lankan) — elevated risk of type 2 diabetes and cardiovascular disease at BMI ≥ 23; some providers use ≥ 25 as the Mounjaro eligibility threshold.
• Black and African-Caribbean backgrounds — higher cardiovascular and diabetes risk at lower BMI; adjusted thresholds of ≥ 25 are used by some providers.
• East and South-East Asian backgrounds — similar to South Asian populations, higher metabolic risk at lower BMI.

A common concern for patients making progress on Mounjaro is what happens when their BMI falls below the standard eligibility threshold of 27 or 30.

The approach varies between providers, but progressive clinical practice allows:

• Continued treatment below the BMI threshold — recognising obesity as a chronic condition requiring ongoing management
• Maintenance dosing — a lower dose (e.g. 2.5mg or 5mg) to sustain results without full active treatment
• Transfer to a new provider with a maintenance programme — if your current provider stops treatment at a threshold

For a full clinical discussion of why abrupt cessation based on BMI is problematic—and the evidence for weight regain—see our guide: Mounjaro BMI Cutoffs: Why Stopping Too Early Can Backfire.

NICE guidance (TA1026) recommends Mounjaro for up to two years initially, subject to clinical review at regular intervals. This is not a fixed endpoint—it is a review point where continued prescription is assessed based on ongoing clinical benefit.

• Standard providers: up to 2 years with periodic clinical reviews
• Progressive providers: long-term maintenance plans beyond 2 years where clinically appropriate
• Regular progress reviews required — weight, metabolic markers, and patient-reported outcomes

Yes—restarting Mounjaro after a break is possible. Most providers require:

• A new medical consultation — to reassess eligibility and health status
• Updated BMI and relevant health markers
• Medical review of any changes since previous treatment

When restarting, providers will almost always begin at the lowest dose (2.5mg) and re-titrate gradually—regardless of the dose you were previously taking. This reduces the risk of side effects and allows your body to readapt.

If you are considering switching providers to restart or continue treatment, see our guide on switching pharmacies for Mounjaro or Wegovy.